United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biohaven Pharmaceutical Hld

NEW HAVEN, Conn. and NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States

It's still not too late to jump aboard the Pfizer train.

Should You Buy Pfizer Stock After the Fantastic COVID-19 Pill News?

According to The Washington Post, Pfizer plans to seek boosters for anyone age 18 and older.

Pfizer will reportedly ask FDA to authorize its booster for all adults

It's Monday on PreMarket Prep Plus, so that means it's time for a “Briefing With Brent.” Brent Slava has been the head of the Benzinga Pro newsdesk since 2013 and has helped investors big and small navigate the financial markets through their ups and downs.

Pfizer's COVID-19 Pill, S&P 500 Rally, 'Sympathy Play Mania' On PreMarket Prep Plus

Great news on Friday morning kept markets buoyant to end yet another strong week in the markets: a better-than-expected Employment Situation and Unemployment Rate — not to mention excellent progress on a new Covid pill from Pfizer (PFE Quick QuotePFE - Free Report) — helped hoist the Nasdaq +0.20%, the S&P 500 +0.37% and the Dow +0.56% in the last full trading session. This capped off five solid weeks of strong market gains, and it continues into this Monday morning: the Dow is +140 points, the S&P 500 +10 and the Nasdaq +2 points in the pre-market.

Markets Up on COVID Pill News

Pfizer's (PFE) COVID-19 pill reduces hospitalizations and deaths substantially

Pfizer (PFE) COVID Pill Shows Strong Efficacy, Stock Rallies

BioNTech SE

Merck

Moderna

Now that the COVID-19 vaccine is available to virtually everyone in the country, I have one favorite among vaccine stocks after earnings. The post Are Vaccine Stocks A Buy On Earnings?

Are Vaccine Stocks A Buy On Earnings?

These are Insider's biggest healthcare stories for November 8.

Why Pfizer's not worried about resistance to its new antiviral

CBRE Group

Gartner

Nucor

ON Semiconductor

Tesla

We have narrowed down our search to five large-cap growth stocks that have strong growth potential for the rest of 2021. These are: TSLA, NUE, ON, IT and CBRE.

Three Encouraging News on U.S. Economic Recovery: 5 Top Picks

Do These 2 Numbers From Pfizer Spell Trouble for Moderna?

According to most health care professionals, Pfizer Inc.'s ( PFE , Financial) Covid-19 vaccine has proven to be effective, and the stock has gained by nearly 25% over the past year as a consequence.

Pfizer Is Still Undervalued

Ameriprise Financial

Franklin Resources

Blackrock Inc

Infosys

KLA-Tencor

Eli Lilly

T. Rowe Price Group

Taiwan Semiconductor Manufacturing

United Microelectronics

Releasing two top November stocks from the MDA Growth and Dividend Breakout monthly portfolio and two top samples from prior portfolios. Long-term dividend portfolios have a 1 year average weighted gain of +20.6%. The best gain is still from the May 2020 portfolio +87.5%.

V&M Breakouts: Top Growth And Dividend Stocks For November 2021

Probably, but there will be room for other players in the COVID-19 vaccine market, too.

Will Moderna and Pfizer Continue to Lead After the COVID-19 Pandemic Ends?

Pfizer (NYSE: PFE) is seeking FDA approval for a COVID-19 pill that is highly effective against severe cases of the coronavirus, lifting pharmaceutical sector-related exchange traded funds but dragging on biotech-related ETFs with exposure to some of the company's biggest competitors. On Friday, the iShares U.S. Pharmaceuticals ETF (NYSEArca: IHE) rose 0.3%, while the VanEck [.

Pfizer's COVID-19 Pill Has Mixed Results for Healthcare ETFs

Merck, Inc. (NYSE: MRK) is locking horns with peer Pfizer, Inc. (NYSE: PFE) in what could be termed as the battle supremacy in the COVID-19 treatment market. The stakes are high, with an effective treatment for the disease potentially entering the arena in addition to the vaccines that are already on the market.

Will Pfizer Outgun Merck With Oral COVID-19 Pill?

Stocks extended their winning streak amid growing optimism about the U.S. economic recovery.

Reopening Stocks Lead The Market Higher After Strong Jobs Report, Pfizer Announcement

With promising updates from Pfizer Inc. ( PFE , Financial) regarding the effectiveness of its oral Covid-19 pills, consumers and investors alike are continuing to carefully watch the health care space.

2 Health Care Stocks to Consider on Covid-19 Treatment Updates

Pfizer Inc. has announced that preliminary findings from an experimental pill used to treat those diagnosed with COVID-19 was extremely effective at preventing death and hospitalization, reports the Wall Street Journal. For those with a mild to moderate COVID-19 infection that took the pill, Paxlovid, within three days of diagnosis, there was an 89% reduction [.

Pfizer's COVID-19 Pill 89% Effective in Those With Positive Diagnosis

Abbott Labs

Chevron

Delta Air Lines

Ford Motor Company

Alphabet

Intel

MGM Resorts

Thomson Reuters

Earnings reports for S&P 500 stocks have been exceptionally good so far. Here are 10 stocks to buy that have delivered in Q3.

10 S&P 500 Stocks to Buy After Winning in Q3

Pfizer's stock soars after it delivers groundbreaking results for its COVID-19 oral antiviral candidate, PAXLOVID.

Pfizer stock jumps, Moderna, Merck tumble

Nonfarm Payrolls Jump in October

Wall Street got a double dose of good news to cheer on Friday. The job market rebounded sharply in October following a disappointing September. And Pfizer surged after issuing positive data about its Covid-19 pill.

Stocks rally to new record highs on strong jobs data and Pfizer Covid pill news

The private sector alone brought 604K jobs, more than a third of which came from the Leisure & Hospitality and Professional & Business Services sectors.

Huge Jobs Number: 531K, 4.6% Unemployment; Did Pfizer Cure Covid?

Pfizer plans to seek the Food and Drug Administration's OK this month for the pill, with doses potentially ready for delivery this year.

Pfizer soars 10% on strong results from COVID-19 pill study, while Moderna and Merck tumble

Pfizer's experimental COVID-19 antiviral pill can cut the risk of ending up in the hospital or dying by 89%, and this means that Americans may soon have a choice in COVID-19 pills that they can take at home.

News for Pfizer Stock (PFE)